Actively Recruiting

Phase 1
Age: 50Years +
All Genders
Healthy Volunteers
NCT03809351

UAB Alzheimer's Disease Center Core Cohort - Tau Imaging Substudy

Led by University of Alabama at Birmingham · Updated on 2025-12-11

160

Participants Needed

1

Research Sites

416 weeks

Total Duration

On this page

Sponsors

U

University of Alabama at Birmingham

Lead Sponsor

N

National Institute on Aging (NIA)

Collaborating Sponsor

AI-Summary

What this Trial Is About

The primary objective of this study is to measure the concentration and the regional brain distribution of pathologic tau deposition using the PET tracer AV-1451 in participants in the UAB-ADC cohort. The amount and distribution of AV-1451 in the brain will be correlated to demographic, clinical, genetic, and biospecimen data acquired through the separate ongoing UAB-ADC study. Assessment of interactions between race and vascular risk factors, brain tau levels measured with AV-1451-PET, and cognitive status will be the primary outcome of this imaging study. Individuals participating in this AV-1451-PET/MRI study will also be enrolled in an ongoing \[C-11\]PiB-PET/MRI study (IRB-300001005, IND-138128), and their amyloid, tau and cognitive statuses will be compared in terms of race and vascular risk factors.

CONDITIONS

Official Title

UAB Alzheimer's Disease Center Core Cohort - Tau Imaging Substudy

Who Can Participate

Age: 50Years +
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Enrollment in the UAB-ADC study under a separate IRB-approved research protocol
  • Enrollment in the UAB-ADC amyloid-PET substudy under a separate IRB-approved research protocol
  • Negative urine or serum hCG test within 2 days of [F-18]AV-1451 administration in women of childbearing potential
  • Women who are post-menopausal with at least 1 year since last menses or documented surgical sterilization do not require pregnancy testing
Not Eligible

You will not qualify if you...

  • Meets any exclusion criteria for the UAB-ADC study
  • Inability or contraindication for undergoing MRI and/or PET imaging
  • Inability to participate in the imaging studies due to severity of dementia

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

UAB

Birmingham, Alabama, United States, 35233

Actively Recruiting

Loading map...

Research Team

C

Chinara Dosse

CONTACT

C

Carol Chambless

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

DIAGNOSTIC

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

UAB Alzheimer's Disease Center Core Cohort - Tau Imaging Substudy | DecenTrialz